AD/PD 2024
AD/PD™ is a conference focuses on basic science and translational and clinical research to bring you the latest findings from clinical trials, somes new insights on disease mechanisms and etiologies or advances in diagnostic markers for example.
The AD/PD™ conference has become one of the must-attend events in the field of neurodegenerative disorders, with over 4,100 participants from 61 countries and more than 2,000 abstracts in 2023.
SynapCell will be presenting new data in a Poster (P0852) on the “Characterization of a Transgenic Mouse Model of Tauopathy Using Quantitative EEG: Does Tau Pathology Lead to Disrupted Spectra?”
We look forward to discussing with you there !
Maïtena AQUIZERATE
Application Specialist
Venceslas DUVEAU
Head of Scientific Sales
POSTER / P0852
Poster Topic: Theme B: Tauopathies / B07.a. Animal Models: Transgenic rodents
Characterization of a Transgenic Mouse Model of Tauopathy Using Quantitative EEG: Does Tau Pathology Lead to Disrupted Spectra?
Dementia is a defining disease in the 21st century, tiggering a decline in cognitive abilities, behavior and psychological well being. Dementia is a known consequence of Alzheimer’s disease, but it is less known that other diseases can also trigger it. Among them, tauopathies and frontotemporal dementia are guilty of triggering this disease.
In order to properly assess the efficacy of therapies, we phenotyped a model of tauopathy to see the impact of misfolded tau accumulation on the EEG spectra.